Important note: Information in this article was accurate in 2008. The state of the art may have changed since the publication date.
Important note: Information in this article was accurate in 2008. The state of the art may have changed since the publication date.
|
|
Reuters NewMedia - July 14, 2008
"Research scientists currently working in HIV will be reassigned to other activities," Linda Dyson, a spokeswoman in Roche's U.S. office in New Jersey, said in an e-mail.
Dyson confirmed an e-mail sent on Wednesday to some activists informing them of the decision. In that e-mail, the company said it "decided to refocus our resources within virology on diseases in which we can deliver substantial improvements over existing medications."
Dyson declined to specify how much Roche has been investing in HIV research.
She also said she could not specify how many employees worked in the HIV research division. Roche employs 5,000 people in the U.S. and 3,000 in its New Jersey office.
The company said in the e-mail to some activists that it initially had been excited about the potential for drugs in pre-clinical testing, but it has "concluded that none would provide a true incremental benefit for patients compared to medicines currently on the market."
Roche said it would continue to support its molecular diagnostic tests and drugs already on the market, including the fusion-inhibitor Fuzeon.
Roche has partnered with Morrisville, North Carolina-based biotech Trimeris Inc to sell Fuzeon, which netted $266.8 million in sales last year.
But the drug struggled because of its cost -- $25,000 for a year's supply -- exceeding the cost of other HIV drugs on the market, said Peter Staley, founder of AIDSmeds.com, which tracks HIV- related news.
The launch of new drugs and an uptick in HIV cases is set to make AIDS medicine a $10.6 billion market by 2015, according to a study published last year by independent market research firm Datamonitor.
More than 20 separate HIV drugs are available, with several combination pills also available. None can cure the fatal disease, which infects an estimated 33 million people globally and which has killed 25 million.
The drugs fall into various classes, each of which interferes with the replication of the virus at a different stage. The human immunodeficiency virus hijacks immune system cells, forcing them to create copies of itself.
Activists said they would not mourn the withdrawal of Roche from the field.
"They're not beloved in the AIDS community," said James Love, Director of Knowledge Ecology International, an advocacy group that focuses on access to medication.
"They are criticized a lot by people in the AIDS field because they are the least willing to give discounts on their AIDS drugs."
The decision reflects "the lack of productivity among the groups that they have working in this area," he said, adding that "a lot of the big pharma companies haven't been very impressive in terms of their big internal pipeline."
Staley said Roche has never come up with an AIDS drug that has sold really well.
"Roche is a big company and they've been trying to get this right for many, many years." Staley said.
"It is disappointing that there is one less big pharmaceutical company in this field. I don't think it's a sign of a serious problem in pharma's commitment."
(Editing by Maggie Fox and Andre Grenon)
080714
RE080710
Copyright © 2008 - Reuters, Ltd. All rights reserved. Republication or redistribution of Reuters content is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Contact Reuters.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Elton John AIDS Foundation UK, the National Library of Medicine, AIDS Walk of Orange County, and donations from users like you.
Always watch for outdated information. This article first appeared in 2008. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2008. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .